A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Patients who had an ASCVD event at an Intermountain hospital will be screened for eligibility to be randomized. Subjects who meet eligibility criteria will be randomized 1:1 to receive targeted care of their LDL-C through a pharmacist-driven management program or not. Patients may opt-out of receiving LDL-C management by the pharmacy team at any time. The purpose of this program is to increase the proportion of patients who achieve guideline-based recommendations of LDL-C levels of \<70 mg/dL by increasing statin and/or LLT adherence and LDL-C testing. Data collection as part of the study will continue until the last person randomized has had 1-year of follow-up.
Sponsor: Intermountain Health Care, Inc.
You may qualify if…
- ✓ 1. Male or female \>18 years of age
- ✓ 2. Receive follow-up care with Intermountain Health
- ✓ 3. Value-based patient (as defined in the EDW)
- ✓ 4. Documentation of an ASCVD diagnosis, by 1 of the following:
- ✓ Coronary artery disease (Primary inpatient CAD diagnosis during index encounter; Primary inpatient MI diagnosis during index encounter; PCI during index encounter; or CABG during index encounter
- ✓ Cerebrovascular accident (Primary inpatient ischemic stroke diagnosis during index encounter; Carotid endarterectomy during index encounter; or Carotid stent during index encounter)
- ✓ Peripheral arterial disease (Bypass or percutaneous intervention during index encounter)
You may not qualify if…
- ✕ 1. Patient age \<18 years.
- ✕ 2. Receipt of or expected receipt of palliative care, expected discharge to hospice, or long-term care facility (i.e., skilled nursing facility).
- ✕ 3. Pregnant or lactating women
Where it's recruiting
Salt Lake City
Source: ClinicalTrials.gov · NCT06571162 · last updated 2025-05-06